Clinical trials
Cord Blood clinical trials
Below are recruiting cord blood clinical trials, each written for real people, not researchers. We’re tracking 98 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06930651RecruitingPhase 1/Phase 2
Engineered NK cell therapy for relapsed blood cancers
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
Houston, TexasAges 18–80 - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT04991870RecruitingPhase 1
Early-stage immune cell therapy for recurrent grade 4 brain tumors
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
Houston, TexasAges 12 years+ - NCT05472558RecruitingPhase 1
CAR-NK cell treatment for CD19-positive relapsed lymphoma
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
Hanzhou, ZhejiangAges 18–75 - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06707259RecruitingPhase 1
Cord blood CAR NK cells for B-cell lymphoma
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT07101432RecruitingPhase 1
Radiation plus engineered NK cells for advanced head and neck cancer
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
Houston, TexasAges 18 years+ - NCT07139509RecruitingPhase 1
Dual-targeting CAR-T cell therapy for relapsed multiple myeloma
This trial tests a new type of immune cell therapy using donated umbilical cord blood cells that are modified to target two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or is not responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody.
Xi’an, ShanxiAges 18–75 - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT07274059RecruitingEarly Phase 1
CAR-T cell therapy from cord blood for lupus
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
Yancheng, JiangsuAges 18–75 - NCT07444632RecruitingPhase 1
Gene-modified cord blood cells for advanced blood cancers
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
Houston, TexasAges 18–75 - NCT07572890RecruitingPhase 1
Experimental treatment study for chronic kidney disease
This research study tests an experimental treatment for people with chronic kidney disease who are not yet on dialysis. The goal is to see if the treatment is safe and how it affects kidney function.
Winter Park, FloridaAges 18–80 - NCT07587047RecruitingPhase 1
Stem cell study for chronic lower back pain
This study tests a stem cell treatment for people with ongoing lower back pain. It aims to see if the therapy can help reduce pain and improve your quality of life.
Winter Park, FloridaAges 18–85 - NCT07622316RecruitingPhase 1
Autism Research Study for Children Ages 3 and Up
This is an early-stage study exploring a new experimental treatment for autism spectrum disorder (ASD). Researchers will work with your child and family to test whether this approach is safe and how it might help with autism symptoms.
Roswell, GeorgiaAges 3 years+ - NCT06827782Enrolling by invitationPhase 1
Cord blood CAR-NK cells for relapsed CNS lymphoma
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06691165RecruitingPhase 1/Phase 2
Low oxygen therapy for blood pressure in spinal cord injury
This trial tests whether breathing low oxygen (hypoxia) can help stabilize blood pressure in people with spinal cord injuries. It's looking for participants with chronic cervical injuries to see if this therapy improves 24-hour blood pressure control.
Kelowna, British ColumbiaAges 19–65 - NCT07488793Recruiting
Remote conditioning for spinal cord injury
This study tests a non-invasive method called remote ischemic conditioning, which involves brief cycles of inflation and deflation of a blood pressure cuff on the arm. It may help improve health outcomes for people with spinal cord injury who are not currently able to exercise.
St Louis, MissouriAges 18 years+ - NCT06906536Enrolling by invitation
Intermittent low oxygen to improve leg function after spinal injury
This trial tests whether short, controlled sessions of low oxygen (like breathing thin air) can improve leg movement and blood markers in people with spinal cord injuries. It may help with walking or standing.
Boulder, ColoradoAges 18–75 - NCT07153211Recruiting
Chemicals in spinal fluid and blood during spinal cord stimulation for nerve pain
This study is testing a spinal cord stimulation treatment for long-term nerve pain. It will look at certain chemicals in your spinal fluid and blood to understand how the treatment works.
BydgoszczAges 18–80 - NCT07588503RecruitingPhase 1
FES Cycling With Blood Flow Restriction for Spinal Cord Injury
This study tests a new exercise method combining electrical stimulation (FES) and controlled blood flow restriction while you cycle. It's designed to improve heart health, blood sugar control, and fitness in people with spinal cord injuries.
Toronto, OntarioAges 18–75 - NCT07227727Recruiting
Blood vessel health after spinal cord injury
This study looks at how spinal cord injury affects the health of your blood vessels. It compares people with paraplegia to those without an injury to understand the differences.
Englewood, ColoradoAges 18 years+
Hear when a new Cord Blood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cord blood?
- Yes. Clin2 currently lists 98 recruiting cord blood studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cord blood trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cord blood trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.